昊海生物科技(06826.HK)前三季淨利跌10.04%至2.51億元
格隆匯10月28日丨昊海生物科技(06826.HK)公佈,截至2019年9月30日止9個月,公司實現營業收入人民幣11.45億元(單位下同),同比增長5.15%;歸屬於母公司股東的淨利潤2.51億元,同比減少10.04%;歸屬於母公司股東的扣除非經常性損益後的淨利潤2.40億元,同比減少4.47%;基本每股收益1.57元。
公告稱,營業收入增長主要是受益於玻璃酸鈉注射液、外用重組人表皮生長因子和人工晶狀體等產品的銷售收入穩步提高,集團營業收入整體較去年同期有所增長。
扣除非經常性損益後歸屬於母公司股東淨利潤下降主要原因是:受醫美終端市場的行業整頓和市場競品數量增加的影響,集團毛利較高的產品玻尿酸銷售收入同比下降較多,導致報告期整體毛利率較去年同期下降2.34%;集團持續加大對於眼科和醫美產品的研發投入,報告期發生的研發費用較去年同期增長人民幣3252.68萬元,增幅高達69.36%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.